Genetic Technologies Ltd Cash Flow Conversion Efficiency
Genetic Technologies Ltd cash flow conversion efficiency. Based on the latest financial reports, Genetic Technologies Ltd (GENE) has a cash flow conversion efficiency ratio of -3.096x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.67 Million) by net assets ($1.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Genetic Technologies Ltd (2000–2024)
Cash flow conversion efficiency of Genetic Technologies Ltd from 2000 to 2024. This chart illustrates how Genetic Technologies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GENE stock price and chart for real-time trading data and today's change.
Genetic Technologies Ltd Cash Flow Conversion Ratio Explained
Genetic Technologies Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Genetic Technologies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genetic Technologies Ltd ranked by their cash flow conversion efficiency. Also see GENE stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Octopus Titan VCT
LSE:OTV2
|
-0.006x |
|
Reliance Global Group, Inc.
NASDAQ:EZRA
|
-0.250x |
|
Mega Sun City Holdings Bhd
KLSE:0081
|
-0.010x |
|
NOROO Paint & Coatings Co Ltd
KO:090355
|
0.064x |
|
333D Ltd
AU:T3D
|
0.084x |
|
ATI Physical Therapy Inc
NYSE:ATIP
|
-0.071x |
|
Lianhua Supermarket Holdings Co. Ltd
F:LSJ
|
2.019x |
|
Realia Properties Inc
V:RLP
|
0.002x |
Annual Cash Flow Conversion Efficiency for Genetic Technologies Ltd (2000–2024)
The table below shows the annual cash flow conversion efficiency of Genetic Technologies Ltd from 2000 to 2024. Review free cash flow generation of Genetic Technologies Ltd to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | $1.83 Million | $-9.68 Million | -5.288x | -507.08% |
| 2023-06-30 | $11.16 Million | $-9.72 Million | -0.871x | -152.89% |
| 2022-06-30 | $16.43 Million | $-5.66 Million | -0.344x | -17.80% |
| 2021-06-30 | $21.53 Million | $-6.30 Million | -0.292x | +28.38% |
| 2020-06-30 | $13.99 Million | $-5.71 Million | -0.408x | +88.09% |
| 2019-06-30 | $1.77 Million | $-6.07 Million | -3.429x | -186.63% |
| 2018-06-30 | $4.71 Million | $-5.64 Million | -1.196x | -85.73% |
| 2017-06-30 | $10.58 Million | $-6.81 Million | -0.644x | +0.95% |
| 2016-06-30 | $11.88 Million | $-7.73 Million | -0.650x | -27.20% |
| 2015-06-30 | $18.96 Million | $-9.69 Million | -0.511x | +91.50% |
| 2014-06-30 | $1.83 Million | $-10.99 Million | -6.012x | -360.56% |
| 2013-06-30 | $5.76 Million | $-7.52 Million | -1.305x | -144.99% |
| 2012-06-30 | $14.40 Million | $-7.67 Million | -0.533x | -262.57% |
| 2011-06-30 | $6.81 Million | $2.23 Million | 0.328x | +143.55% |
| 2010-06-30 | $5.72 Million | $-4.30 Million | -0.753x | -115.70% |
| 2009-06-30 | $17.49 Million | $-6.10 Million | -0.349x | -1815.27% |
| 2008-06-30 | $20.83 Million | $423.68K | 0.020x | -84.38% |
| 2007-06-30 | $16.90 Million | $2.20 Million | 0.130x | +138.82% |
| 2006-06-30 | $18.27 Million | $-6.13 Million | -0.335x | -15.98% |
| 2005-06-30 | $22.75 Million | $-6.58 Million | -0.289x | -9.13% |
| 2004-06-30 | $17.07 Million | $-4.52 Million | -0.265x | -627.25% |
| 2003-06-30 | $27.28 Million | $-993.71K | -0.036x | +65.80% |
| 2002-06-30 | $31.14 Million | $-3.32 Million | -0.107x | -81.95% |
| 2001-06-30 | $38.07 Million | $-2.23 Million | -0.059x | -39.21% |
| 2000-06-30 | $7.58 Million | $-318.68K | -0.042x | -- |
About Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinicall… Read more